Impact News +++ Fermi sinks after receiving subpoena tied to Project Matador (SeekingAlpha) +++ FERMI Aktie -3,64%

EYEPOINT Aktie

>EYEPOINT Aktienkurs

4 EUR -68.8% (TradegateBSX)

Ask: 3.96 EUR / 1270 Stück

Bid: 3.86 EUR / 1300 Stück

Tagesumsatz: 85332 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

EYEPOINT Aktie über LYNX handeln

Intraday

1 Jahr

>EYEPOINT Performance

1 Woche: -1,7%

1 Monat: -2,9%

3 Monate: +1,7%

6 Monate: +2,3%

1 Jahr: +25,7%

laufendes Jahr: -24,9%

>EYEPOINT Aktie

Profil:

EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-relat..
>Volltext..

Insiderhandel:

>EYEPOINT Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>EYEPOINT Peer Group

Gesundheit, Augenmedizin/ Sehhilfen

>EYEPOINT Chart & Kurs - NASDAQ

>EYEPOINT News

17.08.26 - 17:15	Ocular gains on EyePoint phase 3 wet AMD miss (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.08.26 - 16:24	EyePoint Aktie bricht ein: Medikament DURAVYU verfehlt primären Studienendpunkt (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.08.26 - 16:24	Rückschlag für EyePoint bei AMD-Studie beflügelt Aktie von Ocular Therapeutix (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.08.26 - 16:12	EyePoint sinks on Duravyu phase 3 miss (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.08.26 - 13:24	XFRA: PV3B: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL EYEPOINT INC. DL-,01 PV3B US30233G2093 BAW/UFN...

17.08.26 - 13:21	XFRA: INSTRUMENT_SUSPENSION - US30233G2093 (XETRA)
	Instrument ID [5753330] (PV3B - US30233G2093) suspended...

05.08.26 - 13:36	EyePoint Pharmaceuticals GAAP EPS of -$1.09 misses by $0.13, revenue of $0.5M beats by $0.13M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 19:57	EyePoint rises after enrollment update on Duravyu late-stage trials (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 18:30	Mizuho kürt Biotech-Favoriten EyePoint vor entscheidenden Studiendaten (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 13:03	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) (GlobeNewswire EN)
	– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– ...

29.07.26 - 17:30	Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline (Zacks)
	EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

17.07.26 - 17:18	EyePoint to pay $4.6M to settle with DoJ over kickback claims (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.07.26 - 13:06

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

13.07.26 - 13:03	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer (GlobeNewswire EN)
	Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives...

03.07.26 - 00:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Eyepoint Pharmaceuticals im Wert von 73167 USD (Insiderkauf)
	Ribeiro, Ramiro - Vorstand - Tag der Transaktion: 2026-06-30...

16.06.26 - 13:03

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

19.05.26 - 13:03	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire EN)
	WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:...

18.05.26 - 13:03

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

14.05.26 - 13:06	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data (GlobeNewswire EN)
	– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – ...

07.05.26 - 18:00	EyePoint (EYPT) Q1 2026 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Für die typische Frau ist ausschlaggebend das personelle Gefühl, für den typischen Mann das generelle Gefühl. - Ludwig Klages

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram